Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer

Giandomenico Roviello, Daniele Generali

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)1270-1272
Number of pages3
JournalThe Lancet. Oncology
Volume19
Issue number10
DOIs
Publication statusPublished - Oct 2018

Cite this

Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer. / Roviello, Giandomenico; Generali, Daniele.

In: The Lancet. Oncology, Vol. 19, No. 10, 10.2018, p. 1270-1272.

Research output: Contribution to journalArticle

@article{69ed75b6eece4da7936493bc696b352a,
title = "Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer",
author = "Giandomenico Roviello and Daniele Generali",
year = "2018",
month = "10",
doi = "10.1016/S1470-2045(18)30512-6",
language = "English",
volume = "19",
pages = "1270--1272",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "10",

}

TY - JOUR

T1 - Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer

AU - Roviello, Giandomenico

AU - Generali, Daniele

PY - 2018/10

Y1 - 2018/10

U2 - 10.1016/S1470-2045(18)30512-6

DO - 10.1016/S1470-2045(18)30512-6

M3 - Article

C2 - 30217673

VL - 19

SP - 1270

EP - 1272

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 10

ER -